読み込み中
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
最新データ
￥761
−￥5.00 · -0.65%
日中の時刻はJSTです。市場データは遅延する場合があります。
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
日中レンジ
現在 ￥761
52週レンジ
現在 ￥761
日中の時刻はJSTです。市場データは遅延する場合があります。
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
日中レンジ
現在 ￥761
52週レンジ
現在 ￥761
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
